Replies to post #150248 on Biotech Values

[DewDiligence]

FDA expands Actemra label to second-line moderate-to-severe RA:

http://finance.yahoo.com/news/fda-approves-expanded-indication-actemra-153000806.html

The prior FDA label specified Actemra use following failure on a TNF-a drug, specifically, which is the de facto third-line setting, so Actemra can now be considered a second- or third-line agent.

From a practical standpoint, I don’t see the expanded label making much difference; Orencia will continue to outsell Actemra by a wide margin, IMO.